The only reason for spikes in share price since listing has been Covid related, hence the reliance on TGA approval for self-use RAT. Its been almost 2 years since listing and the have only signed 1 contract for non Covid related products, that being for HIV products with Viatris/Mylan.
Even a recent shareholder recommendation from one its major shareholders, Ellerston Capital, speaks only to the upside in shareholder value as a result of TGA approval for self-use RAT.
AT1 Price at posting:
20.0¢ Sentiment: Hold Disclosure: Held
